Businessweek

Seattle Genetics Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplement to the Biologics License Application (sBLA) supporting the use of ADCETRIS (brentuximab vedotin) for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). The FDA is expected to take action on the application by September 14, 2013. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of HL and sALCL, that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL. The sBLA is based on results from a phase 2 clinical trial with two treatment arms. One arm evaluated retreatment with ADCETRIS in patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse. The other arm evaluated extended treatment with ADCETRIS beyond 16 cycles of therapy. The sBLA submission includes updated data sets from this phase 2 trial.

Seattle Genetics Inc. Presents at UBS Global Healthcare Conference, May-21-2013 11:30 AM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Clay B. Siegall, Co-Founder, Chairman, Chief Executive Officer and President.

Seattle Genetics Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the period, the company reported net loss of $16,264,000 or $0.14 per basic and diluted share on total revenue of $57,328,000 against net loss of $12,298,000 or $0.11 per basic and diluted share on total revenue of $48,245,000 a year ago. Loss from operations was $16,387,000 compared to $15,498,000 a year ago.

Seattle Genetics Inc., Q1 2013 Earnings Call, May 07, 2013

Seattle Genetics Inc. announced that they will report Q1, 2013 results at 5:00 PM, Eastern Standard Time on May 07, 2013